Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Lytix Biopharma AS ( (DE:6BG) ).
Lytix Biopharma has completed the subscription period for its subsequent offering, resulting in valid subscriptions for 1,811,803 new shares at NOK 9.00 per share, raising gross proceeds of about NOK 16.3 million. Following the issuance of these shares, the company’s share capital will increase to NOK 7,690,000.50, corresponding to 76,900,005 shares, with trading of the new shares on Euronext Growth Oslo expected to begin in mid-February 2026 once payment and registration are finalized.
The capital raise, though below the maximum targeted NOK 30 million, strengthens Lytix’s financial position as it advances its immuno-oncology pipeline, including lead candidate LTX-315. The transaction, managed by DNB Carnegie with Advokatfirmaet Thommessen as legal advisor, underlines continued investor support and maintains the company’s compliance with disclosure obligations as an Euronext Growth Oslo-listed biotech.
More about Lytix Biopharma AS
Lytix Biopharma AS is a clinical-stage biotech company based in Oslo, Norway, developing cancer immunotherapies derived from host-defense peptide-based molecules. Its lead candidate, LTX-315, is a first-in-class oncolytic molecule designed to boost anti-cancer immunity, supported by a pipeline targeting multiple cancer indications and treatment settings as mono- or combination therapy.
Average Trading Volume: 78,176
Current Market Cap: NOK714.8M
Find detailed analytics on 6BG stock on TipRanks’ Stock Analysis page.